Ratings by Piper Sandler (Do Kim)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 6/8/2022 | Rigel Pharmaceuticals | RIGL | Downgrade | Neutral (Overweight) |
1.76 (1.02) |
-42.05% | Details | |
| 5/19/2022 | Replimune Group | REPL | Maintain | Overweight (N/A) |
|
Details | ||
| 5/17/2022 | Scholar Rock | SRRK | Maintain | Overweight (N/A) |
|
Details | ||
| 5/17/2022 | Gilead Sciences | GILD | Maintain | Neutral (N/A) |
|
Details | ||
| 5/11/2022 | AbCellera Biologics | ABCL | Maintain | Overweight (N/A) |
|
Details | ||
| 5/6/2022 | Vertex | VRTX | Maintain | Neutral (N/A) |
|
Details | ||
| 4/29/2022 | Gilead Sciences | GILD | Maintain | Neutral (N/A) |
|
Details | ||
| 4/22/2022 | Vertex | VRTX | Maintain | Neutral (N/A) |
|
Details | ||
| 4/11/2022 | Affimed Therapeutics | AFMD | Maintain | Overweight (N/A) |
|
Details | ||
| 4/4/2022 | Gilead Sciences | GILD | Maintain | Neutral (N/A) |
|
Details | ||
| 3/31/2022 | Affimed Therapeutics | AFMD | New Coverage | Overweight (N/A) |
4.45 (2.71) |
-39.1% | Details | |
| 3/31/2022 | Travere Therapeutics | TVTX | New Coverage | Overweight (N/A) |
26.05 (24.19) |
-7.14% | Details | |
| 3/31/2022 | Ionis Pharmaceuticals | IONS | New Coverage | Overweight (N/A) |
36.48 (39.25) |
7.59% | Details | |
| 3/31/2022 | Codexis, Inc. | CDXS | New Coverage | Overweight (N/A) |
21.18 (11.44) |
-45.99% | Details | |
| 3/22/2022 | TCR2 Therapeutics | TCRR | Maintain | Overweight (N/A) |
|
Details | ||
| 1/24/2022 | Schrodinger | SDGR | Maintain | Overweight (N/A) |
|
Details | ||
| 1/24/2022 | Gilead Sciences | GILD | Maintain | Neutral (N/A) |
|
Details | ||
| 11/19/2021 | TCR2 Therapeutics | TCRR | New Coverage | Overweight (N/A) |
6.60 (2.86) |
-56.67% | Details | |
| 11/19/2021 | Replimune Group | REPL | New Coverage | Overweight (N/A) |
33.27 (18.52) |
-44.33% | Details | |
| 11/19/2021 | Gilead Sciences | GILD | New Coverage | Neutral (N/A) |
67.46 (63.08) |
-6.49% | Details | |
| 11/19/2021 | Exelixis | EXEL | New Coverage | Overweight (N/A) |
17.88 (22.22) |
24.27% | Details | |
| 11/19/2021 | AbCellera Biologics | ABCL | New Coverage | Overweight (N/A) |
14.82 (10.65) |
-28.14% | Details | |
| 11/19/2021 | Vertex | VRTX | Downgrade | Neutral (Overweight) |
188.25 (292.55) |
55.41% | Details | |
| 11/19/2021 | Scholar Rock | SRRK | New Coverage | Overweight (N/A) |
34.34 (5.96) |
-82.64% | Details | |
| 11/18/2021 | Schrodinger | SDGR | New Coverage | Overweight (N/A) |
44.45 (30.41) |
-31.59% | Details |
